Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT06392711 Sponsor: University of Wisconsin, Madison Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT06392711
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with dry mouth, confirmed by a saliva flow test showing very low saliva production.
  • Your dry mouth is not caused by radiation therapy — it has a medical cause.
  • You are between 18 and 90 years old.
  • You are generally in good enough health to undergo a bone marrow sample procedure while awake (confirm with trial site).
  • You are willing and able to give your informed consent to participate.
  • You have both of your submandibular glands (the saliva glands under your jaw) confirmed by imaging.
  • If you are a woman who could become pregnant, you have a negative pregnancy test before joining.
  • If you could potentially father or become pregnant, you are willing to use an acceptable form of birth control during the study.
  • Your recent blood test results meet certain minimum levels for red blood cells, platelets, and white blood cells (confirm specific values with trial site).

Who may not be able to join:

  • You only have one submandibular gland (saliva gland under your jaw).
  • You have salivary gland stones (sialolithiasis).
  • You have diabetes that is not well controlled (based on a blood sugar level test result).
  • Your dry mouth is believed to be caused by a water pill (diuretic) that you started taking before your dry mouth began and are still taking.
  • You have an untreated oral yeast infection (thrush) at the time of enrollment.
  • You have had cancer within the last 2 years, with some exceptions for certain early-stage or well-treated cancers (confirm with trial site).
  • You are on immune-suppressing medication that has not been at a stable dose for at least 2 months.
  • You regularly need blood transfusions to maintain your health.
  • Your doctor estimates your life expectancy is 6 months or less.
  • You have used any experimental drugs, treatments, or medical devices within the last 30 days.
  • You are currently pregnant, breastfeeding, or plan to become pregnant during the study.
  • You are already participating in another clinical trial that could affect this study's results.
  • The study investigators determine you are not suitable for other reasons (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sara McCoy, MD, PhD, University of Wisconsin, Madison

Phone: 800-622-8922

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
4 October 2024
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of participants experiencing DLT of submandibular pain; Proportion of participants experiencing DLT as serious adverse events (AEs); Proportion of participants experiencing DLT as pre-specified toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov